No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
592 |
4. Check minimum number of eventsNone |
592 |
5. Include endpointsNone |
592 |
6. Filter based on genotype QC (FinnGen only) |
573 |
Control definitions (FinnGen only)
- Control exclude
- H8_INNER
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- H81
- Name in latin
- Vertigo centralis
Similar endpoints
↥List of similar endpoints to
Vertigo of central origin
based on the number of shared cases.
Similar with more cases:
- Disorders of vestibular function (Vertigo)
- Diseases of inner ear
- Diseases of the ear and mastoid process
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 4801 | 3024 | 1740 |
| Only index persons | 3769 | 2372 | 1397 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.07 | 0.09 | 0.05 |
| Only index persons | 0.07 | 0.09 | 0.05 |
| Median age at first event (years) | |||
| Whole population | 70.36 | 71.94 | 67.46 |
| Only index persons | 66.62 | 67.92 | 64.42 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 573 | 347 | 226 |
| Unadjusted period prevalence (%) | 0.12 | 0.12 | 0.10 |
| Median age at first event (years) | 62.60 | 60.55 | 65.76 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 591
- Matched controls
- 5910
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H81.4
ICD-10 Finland
Vertigo of central origin
4503599627370496.0
307.7
590
12
R42
ICD-10 Finland
Dizziness and giddiness
14.7
241.9
418
832
H81.3
ICD-10 Finland
Other peripheral vertigo
60.6
156.1
88
17
H81.1
ICD-10 Finland
Benign paroxysmal vertigo
11.8
131.7
154
172
DFF59
NOMESCO Finland
Other assessment of balance
52.5
98.5
57
12
N07CA01
ATC
betahistine; oral
6.0
58.5
117
232
AA1AD
NOMESCO Finland
CT of head and brain
3.7
53.9
279
1144
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
4.8
41.3
106
258
DFF00
NOMESCO Finland
Pure tone audiometry
4.3
40.9
124
344
H81.2
ICD-10 Finland
Vestibular neuronitis
138.9
37.2
39
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
4.6
36.7
99
250
N17
ICPC
Vertigo/dizziness
3.6
32.6
129
427
PA7AD
NOMESCO Finland
CT angiography of head and neck vasculature
6.4
31.3
54
91
H81.0
ICD-10 Finland
Ménière disease
34.7
30.4
39
12
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
4.6
30.2
77
185
Z01.1
ICD-10 Finland
Examination of ears and hearing
3.0
24.8
128
492
I69.3
ICD-10 Finland
Sequelae of cerebral infarction
3.3
20.8
88
299
DFF50
NOMESCO Finland
Electronystagmography
76.2
19.8
22
*
DFF40
NOMESCO Finland
Otoneurologic examination of vertigo
72.3
18.8
21
*
R51.80
ICD-10 Finland
Headache
2.7
18.6
115
483
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
2.8
18.5
107
433
H81.9
ICD-10 Finland
Disorder of vestibular function, unspecified
45.6
18.4
22
5
N05AB04
ATC
prochlorperazine; systemic, rectal
6.2
17.9
31
52
R11
ICD-10 Finland
Nausea and vomiting
3.1
17.7
82
294
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.4
17.2
156
782
H25.8
ICD-10 Finland
Other senile cataract
2.7
17.1
109
463
SPAT1263
SPAT
Sampling
2.1
16.9
278
1763
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
3.9
16.5
50
136
G45.0
ICD-10 Finland
Vertebro-basilar artery syndrome
5.3
16.2
33
65
B01AC30
ATC
platelet aggregation inhibitors excl. heparin - combinations
3.2
15.7
65
217
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.0
15.1
308
2084
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
3.3
15.0
60
196
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
2.3
14.9
141
715
SPAT1216
SPAT
Assessment of functional ability
2.3
14.7
132
655
N03AX16
ATC
[U] pregabalin
2.2
14.5
165
900
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
2.5
14.4
103
461
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.0
14.3
224
1374
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.0
14.2
205
1221
SPAT1215
SPAT
Assessment of need for medical rehabilitation
4.1
14.0
40
104
R53
ICD-10 Finland
Malaise and fatigue
2.1
14.0
176
997
H02AB04
ATC
methylprednisolone; systemic
2.4
13.6
110
519
UKC02
NOMESCO Finland
Cystoscopy
2.3
13.5
124
619
H82
ICPC
Vertiginous syndrome
6.3
13.5
23
38
G44.2
ICD-10 Finland
Tension-type headache
2.5
13.4
97
436
B01AC07
ATC
dipyridamole; systemic
3.2
13.3
54
178
H90.3
ICD-10 Finland
Sensorineural hearing loss, bilateral
2.2
13.2
139
732
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.0
12.9
201
1222
L28
ICPC
Limited function/disability (L)
2.2
12.9
138
731
R07.4
ICD-10 Finland
Chest pain, unspecified
2.0
12.9
193
1159
Z01.8
ICD-10 Finland
Other specified special examinations
2.1
12.8
148
808
Z75.1
ICD-10 Finland
Person awaiting admission to adequate facility elsewhere
4.8
12.7
29
63
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
2.2
12.6
126
650
NB1BA
NOMESCO Finland
Shoulder extensive X-ray examination without contrast
4.1
12.4
35
90
A02BC05
ATC
esomeprazole; systemic
1.9
12.4
260
1740
M54.5
ICD-10 Finland
Low back pain
1.9
12.1
217
1378
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
4.7
12.0
28
62
N02AX02
ATC
tramadol; systemic, rectal
1.8
11.8
273
1878
M53.0
ICD-10 Finland
Cervicocranial syndrome
2.7
11.4
65
259
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
4.4
11.4
29
69
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.1
11.3
117
609
PA6DE
NOMESCO Finland
Neck artery ultrasound examination with Doppler method
3.2
11.3
45
147
I63.5
ICD-10 Finland
Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries
5.7
11.2
21
38
M01AE02
ATC
naproxen; oral, rectal
1.8
11.1
333
2460
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.1
11.1
122
651
S06.0
ICD-10 Finland
Concussion
2.4
11.0
80
359
M03BX02
ATC
tizanidine; oral
1.8
11.0
339
2524
SPAT1149
SPAT
Suture or treatment of traumatic wound
2.3
10.9
94
454
N03AE01
ATC
clonazepam; systemic
3.2
10.9
45
150
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
1.8
10.9
217
1416
A02BC02
ATC
pantoprazole; systemic
1.9
10.8
408
3219
SPAT1229
SPAT
Assessment of need for aid
2.6
10.8
67
279
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.1
10.6
118
632
Z03.8
ICD-10 Finland
Observation for other suspected diseases and conditions
3.2
10.4
42
138
X59
ICD-10 Finland
Exposure to unspecified factor
2.1
10.4
117
628
T90.5
ICD-10 Finland
Sequelae of intracranial injury
10.9
10.3
19
18
M50.3
ICD-10 Finland
Other cervical disc degeneration
5.0
10.3
22
45
NH1BA
NOMESCO Finland
Ankle extensive X-ray examination
5.0
10.3
22
45
DE2CG
NOMESCO Finland
Acoustic channel extensive MRI examination with high intensity magnet
10.3
10.1
19
19
K21.9
ICD-10 Finland
Gastro-oesophageal reflux disease without oesophagitis
2.4
10.0
73
328
UDC00
NOMESCO Finland
Ear microscopy
2.6
9.9
58
234
NA1AD
NOMESCO Finland
Cervical spine CT examination
3.1
9.9
41
137
DAX00
NOMESCO Finland
Adjustment or review of hearing aid
2.8
9.7
49
183
R51
ICD-10 Finland
Headache
3.2
9.7
40
133
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.4
9.7
70
313
J37.0
ICD-10 Finland
Chronic laryngitis
3.7
9.6
31
88
Z01.2
ICD-10 Finland
Dental examination
1.7
9.5
242
1684
Z46.1
ICD-10 Finland
Fitting and adjustment of hearing aid
2.6
9.4
57
235
PA6AD
NOMESCO Finland
CT of neck arteries
4.2
9.3
25
62
G45.9
ICD-10 Finland
Transient cerebral ischaemic attack, unspecified
2.4
9.1
64
283
G43.1
ICD-10 Finland
Migraine with aura [classical migraine]
2.9
9.0
42
150
I49.9
ICD-10 Finland
Cardiac arrhythmia, unspecified
2.2
9.0
86
432
UJF30
NOMESCO Finland
Ileoscopy through colon
2.3
9.0
71
330
N06AX21
ATC
duloxetine; oral
2.3
9.0
75
357
N02BE01
ATC
paracetamol; systemic, rectal
2.2
9.0
523
4587
SPAT1104
SPAT
Monitoring of emergency patient
2.7
8.9
48
186
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
2.7
8.9
48
186
NH1AD
NOMESCO Finland
Ankle and foot CT
5.0
8.9
19
39
SPAT1097
SPAT
Recording of ECG
2.0
8.8
102
551
A06AC01
ATC
ispaghula (psylla seeds); oral
1.8
8.8
174
1121
N06AX11
ATC
mirtazapine; oral
1.7
8.8
210
1428
H02AB06
ATC
prednisolone; systemic
1.7
8.7
286
2115
P76
ICPC
Depressive disorder
3.0
8.7
38
131
N28
ICPC
Limited function/disability (N)
7.8
8.7
19
25
A06AC51
ATC
ispaghula, combinations; oral
2.9
8.6
42
154
R03BA05
ATC
fluticasone; inhalant
1.9
8.5
112
634
C07AB02
ATC
metoprolol; systemic
1.8
8.4
149
927
F32.9
ICD-10 Finland
Depressive episode, unspecified
2.2
8.4
71
340
N03AX12
ATC
[U] gabapentin; oral
2.0
8.3
108
607
TAB00
NOMESCO Finland
Lumbar puncture
3.1
8.3
35
118
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
2.5
8.3
55
236
H53.2
ICD-10 Finland
Diplopia
3.5
8.3
29
87
F41.09
ICD-10 Finland
UNS Panic Syndrome
4.5
8.2
20
46
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
1.9
8.1
107
604
N06AA09
ATC
amitriptyline; systemic
2.2
8.1
68
324
SPAT1254
SPAT
Administration of medicine
2.0
8.1
101
560
G47.3
ICD-10 Finland
Sleep apnoea
1.9
8.1
127
761
SPAT1256
SPAT
Intramuscular and subcutaneous injection
1.7
8.0
245
1767
J01MA02
ATC
ciprofloxacin; systemic
1.7
8.0
236
1686
H93.1
ICD-10 Finland
Tinnitus
2.6
8.0
47
190
H53.1
ICD-10 Finland
Subjective visual disturbances
2.7
8.0
45
178
R06AE07
ATC
cetirizine; oral
1.7
7.9
240
1726
J01DB01
ATC
cefalexin; oral
1.8
7.9
466
3978
A04
ICPC
Weakness/tiredness general
2.0
7.9
97
534
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.1
7.9
83
433
JC2KB
NOMESCO Finland
Functional X-ray examination of swallowing
6.1
7.7
20
34
M02AA10
ATC
ketoprofen; topical
1.9
7.6
99
557
NA1BA
NOMESCO Finland
Cervical spine extensive X-ray examination without contrast
10.2
7.6
14
14
H90.4
ICD-10 Finland
Sensorineural hearing loss, unilateral with unrestricted hearing on the contralateral side
3.2
7.5
30
98
F32.10
ICD-10 Finland
Moderate depressive episode without somatic syndrome
2.6
7.5
45
184
N03AX09
ATC
lamotrigine; oral
3.0
7.5
32
109
D82
ICPC
Teeth/gum disease
1.7
7.5
188
1285
N05BA12
ATC
alprazolam; oral
2.2
7.4
67
329
R10.1
ICD-10 Finland
Pain localized to upper abdomen
1.9
7.4
112
661
SPAT1153
SPAT
Removal of sutures
1.7
7.4
193
1333
G35
ICD-10 Finland
Multiple sclerosis
7.0
7.3
17
25
J01MA12
ATC
levofloxacin; systemic
1.8
7.3
117
704
N06CA01
ATC
amitriptyline and psycholeptics; systemic
2.1
7.3
68
339
SPAT1083
SPAT
Initiation and monitoring of IV fluid therapy
3.0
7.2
31
106
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.6
7.2
222
1595
N06AX16
ATC
venlafaxine; oral
2.0
7.2
83
447
JN3AD
NOMESCO Finland
Abdominal CT examination
2.1
7.2
73
376
SPAT1156
SPAT
Guidance concerning treatment of rash and skin
1.9
7.1
92
515
M01AE03
ATC
ketoprofen; systemic, rectal
1.6
7.1
224
1616
W00
ICD-10 Finland
Fall on same level involving ice and snow
2.1
7.1
70
356
SPAT1231
SPAT
Assessment of adjustments needed in living environment
3.7
7.1
22
61
109
Kela drug reimbursment
Multiple sclerosis
8.9
7.1
14
16
N06AB10
ATC
escitalopram; oral
1.8
7.0
107
632
SPAT1211
SPAT
Application of soft bandage
2.2
7.0
60
288
SPAT1137
SPAT
Taking care of patient’s/customer’s hygiene
2.3
7.0
52
235
XKD06
NOMESCO Finland
Physiologic investigation of micturition
3.1
7.0
29
97
TNX33
NOMESCO Finland
Custom moulded cast, unspecified region
2.7
7.0
38
148
L57.0
ICD-10 Finland
Actinic keratosis
2.0
7.0
82
445
DAX08
NOMESCO Finland
Fitting of hearing aid
2.4
6.9
47
204
R35
ICD-10 Finland
Polyuria
2.4
6.9
47
204
SPAT1306
SPAT
Counselling and guidance related to nutrition and weight management
1.9
6.9
86
476
SPAT1234
SPAT
Support of social functional capacity
2.5
6.9
43
180
NH3BA
NOMESCO Finland
Foot and toes extensive X-ray examination
3.1
6.9
28
93
H04.10
ICD-10 Finland
Dry eye syndrome
2.0
6.8
72
375
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
1.8
6.8
106
630
G40.9
ICD-10 Finland
Epilepsy, unspecified
3.2
6.8
27
88
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
2.9
6.8
31
110
SPAT1360
SPAT
Extensive global examination
2.4
6.8
46
200
N03AF02
ATC
oxcarbazepine; oral
3.5
6.8
23
68
A03FA01
ATC
metoclopramide; systemic, rectal
1.7
6.8
139
897
SPAT1262
SPAT
Handing over of treatment supplies
1.8
6.7
108
648
K21.0
ICD-10 Finland
Gastro-oesophageal reflux disease with oesophagitis
2.1
6.7
65
328
A04AA01
ATC
ondansetron; systemic, rectal
2.2
6.7
54
253
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
1.9
6.6
82
452
Z97.4
ICD-10 Finland
Presence of external hearing-aid
2.5
6.6
42
177
SPAT1312
SPAT
General health counselling
1.6
6.6
178
1233
J01FA10
ATC
azithromycin; systemic
1.6
6.6
298
2331
G04CA01
ATC
alfuzosin; oral
2.0
6.6
73
388
M50.1
ICD-10 Finland
Cervical disc disorder with radiculopathy
3.0
6.5
28
96
G43.9
ICD-10 Finland
Migraine, unspecified
2.7
6.5
34
130
M70.6
ICD-10 Finland
Trochanteric bursitis
1.9
6.4
86
487
N03AX11
ATC
topiramate; oral
3.8
6.4
19
51
AA1CD
NOMESCO Finland
Very extensive CT of head and brain
4.1
6.4
17
42
M79.6
ICD-10 Finland
Pain in limb
1.6
6.4
234
1742
NF1AA
NOMESCO Finland
Hip X-ray examination
2.1
6.4
65
335
DE2BG
NOMESCO Finland
Acoustic channel MRI examination with high intensity magnet
8.3
6.4
13
16
N06AB04
ATC
citalopram; systemic
1.7
6.3
130
837
NBG10
NOMESCO Finland
Acromioplastia
3.4
6.3
22
66
R10.0
ICD-10 Finland
Acute abdomen
3.4
6.3
22
66
A07AA02
ATC
nystatin; oral
2.4
6.3
44
194
N06AX26
ATC
vortioxetine; oral
2.4
6.3
41
175
XKD00
NOMESCO Finland
Uroflowmetry
1.8
6.3
93
544
S93.4
ICD-10 Finland
Sprain and strain of ankle
2.2
6.2
54
261
K08.1
ICD-10 Finland
Loss of teeth due to accident, extraction or local periodontal disease
2.0
6.2
72
389
R12
ICD-10 Finland
Heartburn
2.3
6.2
48
222
TNX50
NOMESCO Finland
Removal of cutom molded cast and internal stretch
2.7
6.1
33
128
C08CA05
ATC
nifedipine; systemic
2.2
6.1
49
229
WZA90
NOMESCO Finland
Other medical or dental certificate
1.7
6.1
125
803
SPAT1148
SPAT
Treatment of chronic ulcer or burn
1.8
6.1
90
526
SFC01
NOMESCO Finland
Additional procedure necessary for restorative treatment
1.7
6.1
142
945
Z01.6
ICD-10 Finland
Radiological examination, not elsewhere classified
2.1
6.1
59
298
S01CA01
ATC
dexamethasone and antiinfectives; ophthalmic
1.6
6.0
227
1693
C09CA06
ATC
candesartan; oral
1.7
6.0
133
872
R00.2
ICD-10 Finland
Palpitations
2.2
6.0
49
231
J01DA09
ATC
[U] cefadroxil
1.6
6.0
148
999
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
184
584
4.12
51.42
4.8
4.7
32.75
32.23
%
0.22
126
387
339
1904
2.83
33.59
5.0
3.9
36.19
56.32
ng/l
0.54
266
1403
417
2789
2.68
26.42
4.6
4.5
6.70
6.75
mmol/l
0.23
393
2621
267
1498
2.43
24.09
2.3
2.1
132.14
257.50
u/l
1.66
253
1403
73
200
4.02
23.95
4.0
4.2
24.48
25.11
mmol/l
1.20
66
190
91
303
3.37
22.32
3.5
3.6
0.93
1.98
mmol/l
1.42
66
231
359
2345
2.35
22.22
17.8
15.9
1.36
1.27
inr
0.63
71
674
93
326
3.20
20.93
3.5
3.5
5.14
5.13
kpa
0.02
85
316
68
200
3.71
20.10
2.2
1.9
—
—
—
0
0
64
185
3.76
19.39
2.0
1.7
—
—
—
0
0
254
1567
2.09
16.54
3.2
3.2
1117.95
1583.63
ng/l
2.01
205
1334
392
2847
2.12
16.25
4.0
3.1
52.92
48.62
u/l
0.34
354
2632
304
2058
1.98
14.77
2.3
2.0
104.91
95.44
pmol/l
1.96
178
1058
236
1487
1.98
13.90
3.0
2.4
58.54
59.40
u/l
0.05
213
1377
338
2458
1.88
12.41
6.2
6.3
1.22
1.22
mmol/l
1.07
278
2082
178
1050
1.99
12.41
2.0
1.8
1042.57
1200.74
nmol/l
1.24
120
777
438
3480
2.00
12.12
5.4
4.1
13.14
13.08
mm/h
0.03
398
3186
309
2207
1.84
11.80
6.7
5.7
27.52
26.96
%
0.36
276
2065
22
40
5.67
11.72
1.0
1.1
—
—
—
0
0
303
2173
1.81
11.21
6.0
5.5
57.41
57.88
%
0.25
269
2035
27
63
4.44
10.87
1.9
1.5
—
—
—
0
0
27
63
4.44
10.87
1.9
1.5
—
—
—
0
0
27
63
4.44
10.87
1.9
1.5
—
—
—
0
0
278
1962
1.79
10.70
2.5
2.3
80.45
77.90
nmol/l
0.76
237
1736
195
1243
1.85
10.47
1.7
1.5
21.04
20.69
nmol/l
0.10
159
1041
305
2232
1.76
10.19
5.4
5.5
1.22
1.21
mmol/l
1.04
252
2022
23
50
4.75
10.08
1.1
1.1
—
—
—
0
0
27
67
4.17
10.06
1.7
2.9
43.00
32.24
mg/l
—
8
21
181
1139
1.85
10.06
2.6
2.3
—
—
—
0
0
26
63
4.27
9.99
1.9
1.5
—
—
—
0
0
26
63
4.27
9.99
1.9
1.5
—
—
—
0
0
26
64
4.20
9.79
1.9
1.5
—
—
—
0
0
22
49
4.62
9.37
1.1
1.1
—
—
—
0
0
71
325
2.35
9.31
1.9
1.7
—
—
—
0
0
20
27
7.63
8.99
1.1
1.0
—
—
—
0
0
194
1285
1.76
8.91
2.6
2.1
3.10
3.14
mg/l
0.08
156
1092
162
1019
1.81
8.86
1.7
1.6
0.90
1.26
mg/l
1.29
115
785
523
4593
2.21
8.84
19.8
15.1
17.81
24.37
mg/l
6.53
454
3659
85
432
2.13
8.65
2.0
1.8
370.82
380.71
nmol/l
0.15
68
388
425
3532
1.72
7.99
5.0
4.0
15.27
14.88
pmol/l
2.47
367
3154
385
3117
1.67
7.98
7.0
4.8
34.67
4566.18
e6/l
—
6
61
19
32
6.10
7.43
1.1
1.1
45.59
34.92
mg/l
0.40
14
26
122
742
1.81
7.32
1.2
1.2
7.93
12.85
u/ml
0.47
36
272
164
1090
1.70
7.21
1.6
1.8
420.08
13371864.61
pmol/l
0.80
130
875
485
4255
1.78
6.71
6.5
4.8
1.99
2.22
mu/l
0.36
424
3846
431
3673
1.64
6.55
7.7
7.3
79.19
78.90
u/l
0.03
395
3432
30
108
2.87
6.41
2.0
1.4
—
—
—
0
0
500
4452
1.80
6.23
5.9
4.8
6.10
6.00
mmol/l
0.77
424
4019
18
36
5.12
6.23
1.1
1.2
—
75.60
—
0
5
17
33
5.27
6.05
1.9
1.3
—
—
—
0
0
17
33
5.27
6.05
1.9
1.3
—
—
—
0
0
315
2528
1.53
5.96
5.5
6.0
10.48
11.62
umol/l
1.88
298
2395
13
18
7.36
5.95
2.9
2.8
35423.08
38222.50
ug/l
0.38
13
18
523
4742
1.89
5.85
22.3
17.9
139.52
139.60
mmol/l
0.27
511
4614
279
2189
1.52
5.83
2.9
2.6
—
—
—
0
0
32
126
2.63
5.80
1.5
1.6
—
—
—
0
0
523
4755
1.87
5.61
22.3
18.1
3.99
3.98
mmol/l
0.38
509
4622
53
268
2.07
5.46
1.3
1.2
98.11
141.00
iu/ml
0.54
18
101
14
25
5.71
5.40
2.1
1.2
—
—
—
0
0
14
25
5.71
5.40
2.1
1.2
—
—
—
0
0
11
14
7.98
5.36
5.2
2.2
—
—
—
0
0
95
588
1.73
5.29
6.0
7.5
—
—
—
0
0
14
26
5.49
5.25
2.3
2.3
—
—
—
0
0
141
969
1.60
5.25
1.4
1.2
3.52
1.82
u/ml
0.44
24
246
482
4307
1.65
5.21
16.9
14.5
76.22
76.71
ml/min/173m2
0.20
419
3577
270
2139
1.48
5.19
3.9
4.3
35.11
35.10
g/l
0.02
236
1985
122
817
1.62
5.04
2.2
1.9
—
—
—
0
0
25
94
2.73
4.97
1.0
1.2
3.56
3.91
e6/l
0.06
16
75
25
94
2.73
4.97
1.2
1.2
300.00
1299.12
e6/l
0.40
19
77
117
781
1.62
4.88
1.3
1.2
21.74
36.97
iu/ml
1.63
34
260
475
4251
1.60
4.85
8.1
6.1
41.25
40.38
mmol/mol
1.15
410
3912
8
8
10.12
4.53
1.3
1.5
—
—
—
0
0
17
54
3.21
4.52
1.2
1.1
1.00
12.44
iu/ml
—
5
9
62
355
1.83
4.49
1.8
1.6
—
—
—
0
0
72
433
1.75
4.43
1.8
3.1
66.49
66.40
g/l
0.03
60
387
16
50
3.26
4.36
1.4
1.9
—
—
—
0
0
523
4833
1.71
4.26
12.7
10.6
24.56
24.62
u/l
0.02
496
4642
33
154
2.21
4.20
1.7
1.2
—
—
—
0
0
473
4272
1.54
4.19
4.9
4.0
1.29
1.26
mmol/l
0.43
414
3852
25
104
2.47
4.11
1.2
1.2
—
—
—
0
0
15
47
3.25
4.08
1.5
2.0
—
—
—
0
0
305
2547
1.41
4.07
2.8
2.8
—
—
—
0
0
38
191
2.06
4.02
1.9
2.2
35.69
41.33
u/l
0.96
33
165
41
213
1.99
3.97
1.0
1.0
—
—
—
0
0
250
2035
1.40
3.80
3.0
2.7
124.06
128.15
ug/l
0.13
218
1852
316
2678
1.39
3.75
7.2
9.0
4.22
4.15
e9/l
0.20
277
2344
38
199
1.97
3.62
1.7
1.9
1.28
3.30
ug/l
0.67
25
173
103
716
1.53
3.58
2.1
2.3
2.38
2.32
g/l
0.44
90
656
110
782
1.50
3.43
2.1
2.3
11.66
12.64
umol/l
0.71
99
719
73
474
1.62
3.40
2.9
3.3
2.84
2.05
mmol/l
1.21
64
387
9
18
5.06
3.38
1.2
1.6
—
—
—
0
0
533
5016
1.64
3.21
29.2
22.6
249.32
247.20
e9/l
0.28
525
4871
533
5017
1.64
3.19
28.9
22.7
39.01
39.61
%
1.05
504
4657
533
5018
1.63
3.18
29.1
22.6
4.41
4.42
e12/l
0.11
524
4857
533
5021
1.63
3.13
29.4
22.7
132.97
133.09
g/l
0.07
528
4931
9
20
4.55
3.12
1.2
1.2
—
—
—
0
0
43
250
1.78
3.01
2.7
3.1
4.24
4.45
pmol/l
0.65
33
211
95
678
1.48
2.91
2.2
2.4
19.14
21.89
%
1.24
80
577
9
23
3.96
2.78
1.8
2.1
—
—
—
0
0
9
23
3.96
2.78
1.8
2.1
—
—
—
0
0
9
23
3.96
2.78
1.8
2.1
—
—
—
0
0
478
4432
1.41
2.75
5.6
4.5
1.42
1.49
mmol/l
2.72
419
4032
106
785
1.43
2.67
2.2
3.0
0.83
0.82
mmol/l
0.23
93
732
172
1386
1.34
2.59
5.3
5.3
3.74
2.67
ug/l
0.54
145
1216
480
4468
1.40
2.57
5.5
4.5
4.51
4.59
mmol/l
0.80
422
4095
8
20
4.04
2.57
1.5
1.5
—
—
—
0
0
88
634
1.46
2.57
3.8
4.8
1.03
1.03
mmol/l
0.05
77
569
5
7
7.19
2.55
1.0
1.1
—
—
—
0
0
5
7
7.19
2.55
1.0
1.1
—
—
—
0
0
62
416
1.55
2.54
2.8
3.6
62.79
84.15
ng/l
2.06
48
360
10
31
3.26
2.52
1.1
1.3
—
—
—
0
0
10
31
3.26
2.52
1.1
1.3
—
—
—
0
0
489
4570
1.41
2.52
5.8
5.1
2.63
2.67
mmol/l
0.34
426
4162
184
1504
1.32
2.51
4.3
3.8
10.49
8.65
mg/mmol
0.16
107
941
152
1212
1.34
2.45
2.8
2.7
15084.17
8511.47
umol/l
0.47
128
1047
7
17
4.15
2.36
1.9
1.2
—
—
—
0
0
268
2319
1.28
2.36
5.2
4.0
0.00
0.00
estimate
-0.00
48
475
272
2361
1.28
2.32
5.0
4.0
0.00
0.00
estimate
-0.00
41
431
268
2322
1.28
2.32
7.6
5.4
0.00
0.00
estimate
0.50
43
435
9
28
3.25
2.31
1.8
1.9
—
—
—
0
0
9
28
3.25
2.31
1.8
1.9
—
—
—
0
0
27
152
1.81
2.15
1.4
1.6
—
—
—
0
0
10
36
2.81
2.14
1.0
1.2
—
—
—
0
0
25
138
1.85
2.12
1.5
1.5
223.39
279.92
ug/g
0.81
17
81
77
563
1.42
2.10
4.1
3.8
233.34
246.11
u/l
0.58
70
531
20
105
1.94
1.98
4.0
4.1
29.58
29.64
mg/l
—
10
66
5
11
4.57
1.94
1.2
1.4
—
—
—
0
0
211
1807
1.26
1.93
5.6
4.2
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
7
22
3.21
1.88
1.0
1.2
—
—
—
0
0
175
1470
1.27
1.88
2.5
2.9
30.21
31.93
u/l
0.43
160
1401
15
72
2.11
1.87
1.7
1.8
—
—
—
0
0
5
12
4.19
1.82
1.2
1.2
13.00
25.86
%
—
5
7
5
12
4.19
1.82
1.0
1.2
—
—
—
0
0
5
12
4.19
1.82
1.2
1.1
—
—
—
0
0
20
111
1.83
1.70
1.2
1.1
—
—
—
0
0
6
19
3.18
1.66
1.0
1.2
—
—
—
0
0
18
98
1.86
1.63
2.2
2.0
173.86
5322.52
u/l
—
7
30
200
1735
1.23
1.58
2.3
3.3
2.34
2.35
mmol/l
0.32
139
1491
78
985
0.76
1.46
2.8
2.9
2.44
2.45
mmol/l
0.43
67
851
18
102
1.79
1.46
2.8
3.3
22.38
3417.48
u/ml
0.78
18
97
55
407
1.39
1.45
4.0
6.6
10.16
10.53
mmol/l
0.13
49
379
6
22
2.74
1.43
1.0
1.2
—
—
—
0
0
26
165
1.60
1.42
2.9
3.3
—
—
—
0
0
30
198
1.54
1.40
1.6
2.6
7.36
7.48
g/l
0.21
24
175
30
198
1.54
1.40
1.6
2.6
—
—
—
0
0
30
198
1.54
1.40
1.6
2.6
3.30
3.56
g/l
0.48
24
175
18
104
1.75
1.38
1.3
1.4
—
—
—
0
0
5
17
2.96
1.36
3.0
3.1
—
—
—
0
0
5
17
2.96
1.36
3.0
3.1
—
—
—
0
0
5
17
2.96
1.36
2.0
1.3
140.00
108.40
nmol/l
—
5
10
95
771
1.28
1.34
3.4
3.0
2.87
2.56
e6/l
0.16
63
427
11
54
2.06
1.33
3.6
2.3
—
—
—
0
0
61
466
1.34
1.33
2.6
2.1
0.20
0.21
g/l
0.12
56
435
170
1475
1.21
1.32
3.5
3.1
6.47
7.06
mmol/l
1.01
130
1228
35
243
1.47
1.31
1.2
2.0
1.74
1.52
g/l
0.87
28
212
12
217
0.54
1.29
1.1
1.3
—
—
—
0
0
5
18
2.79
1.28
1.2
1.3
187.64
174.06
pmol/l
—
5
18
9
45
2.02
1.23
1.8
1.8
—
—
—
0
0
9
45
2.02
1.23
1.8
1.8
—
—
—
0
0
9
45
2.02
1.23
1.8
1.8
—
—
—
0
0
16
93
1.74
1.22
2.3
2.2
16.61
15.53
%
—
8
40
5
19
2.64
1.22
1.0
1.4
—
—
—
0
0
196
1740
1.19
1.18
3.6
3.2
—
—
—
0
0
27
183
1.50
1.15
1.7
2.6
2.56
3.01
g/l
1.43
21
160
25
362
0.68
1.11
1.7
2.6
58.00
62.58
ml/min/173m2
—
10
148
41
304
1.37
1.10
1.3
1.4
—
—
—
0
0
17
105
1.64
1.07
1.2
1.8
1102.70
22861.31
e6/l
—
10
78
6
121
0.49
1.06
1.0
1.5
—
—
—
0
0
14
83
1.70
1.02
1.6
1.8
—
—
—
0
0
33
245
1.37
0.91
2.8
2.1
11.43
12.63
nmol/l
0.26
27
213
19
127
1.51
0.89
2.0
2.5
40.39
101.05
ug/min
—
10
71
24
171
1.42
0.84
1.7
2.9
1.09
1.07
g/l
0.01
18
144
47
581
0.79
0.79
2.2
1.9
—
—
—
0
0
12
74
1.63
0.78
1.6
1.7
—
—
—
0
0
12
74
1.63
0.78
1.6
1.7
—
—
—
0
0
0
27
0.00
0.77
0.0
1.6
—
—
—
0
0
0
27
0.00
0.77
0.0
1.6
—
—
—
0
0
19
132
1.45
0.77
1.1
1.4
—
—
—
0
0
14
91
1.55
0.75
1.0
1.4
155.37
268.28
miu/ml
—
8
48
79
676
1.19
0.73
1.5
1.4
—
—
—
0
0
9
55
1.65
0.73
1.4
1.3
—
—
—
0
0
25
185
1.37
0.73
1.6
2.6
10.12
10.53
g/l
0.16
18
161
52
427
1.24
0.72
1.8
2.4
4.50
5.36
ug/l
0.33
34
375
9
56
1.62
0.72
1.2
1.1
—
—
—
0
0
16
109
1.48
0.71
1.6
1.8
—
—
—
0
0
65
552
1.20
0.67
2.7
4.1
3.37
33.53
ug/l
1.36
47
467
7
44
1.60
0.65
1.4
1.2
—
—
—
0
0
7
44
1.60
0.65
1.1
1.1
13.14
12.26
u/l
—
7
39
8
127
0.62
0.64
1.9
1.5
—
—
—
0
0
16
112
1.44
0.64
1.5
1.8
—
—
—
0
0
6
102
0.58
0.62
1.7
1.5
—
—
—
0
0
9
137
0.65
0.61
1.1
1.2
—
—
—
0
0
49
583
0.83
0.61
2.1
1.8
—
—
—
0
0
36
439
0.81
0.57
2.6
2.2
112.79
31.64
u/l
0.51
29
367
19
142
1.35
0.55
1.4
1.6
—
—
—
0
0
11
74
1.50
0.53
1.2
1.1
—
—
—
0
0
10
66
1.52
0.53
1.2
1.2
—
—
—
0
0
9
136
0.66
0.52
1.1
1.2
—
—
—
0
0
9
64
1.41
0.51
1.1
1.1
—
—
—
0
0
16
118
1.37
0.50
1.2
1.3
—
—
—
0
0
92
830
1.13
0.47
3.3
2.8
1.36
1.08
e6/l
0.24
58
481
12
164
0.73
0.45
1.7
1.7
—
—
—
0
0
10
69
1.46
0.44
2.1
2.3
—
777.40
—
0
5
50
434
1.17
0.44
1.7
1.6
1.50
1.50
%
0.00
43
374
9
131
0.68
0.43
1.9
1.7
—
—
—
0
0
5
32
1.57
0.42
1.0
1.6
—
275.00
—
0
6
101
1102
0.90
0.42
4.4
4.5
23.31
21.48
%
0.46
60
544
0
15
0.00
0.41
0.0
1.9
—
2.37
—
0
6
8
59
1.36
0.41
2.1
1.4
—
—
—
0
0
20
159
1.27
0.40
1.8
2.7
38.78
37.43
g/l
0.27
13
136
5
34
1.47
0.40
1.8
1.2
—
—
—
0
0
7
101
0.69
0.40
1.3
1.4
—
—
—
0
0
7
101
0.69
0.40
1.3
1.4
—
—
—
0
0
11
147
0.74
0.37
1.6
1.3
30.33
27.34
iu/l
0.12
11
127
60
668
0.89
0.36
1.5
1.4
—
—
—
0
0
6
42
1.43
0.35
1.2
1.0
—
—
—
0
0
12
92
1.31
0.32
1.4
1.5
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
19
157
1.22
0.30
1.7
2.2
0.54
0.37
u/ml
—
9
91
120
1274
0.93
0.29
5.0
4.2
0.00
0.00
estimate
0.50
41
422
99
926
1.08
0.28
4.9
3.8
105.10
376.66
ng/l
1.88
74
765
8
65
1.23
0.27
1.4
1.6
—
—
—
0
0
19
160
1.19
0.25
2.8
3.8
—
1.38
—
0
14
5
40
1.25
0.22
1.2
1.6
—
—
—
0
0
99
1046
0.94
0.22
5.6
4.2
1.02
1.02
kg/l
0.03
27
160
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
8
105
0.76
0.21
1.3
1.2
—
—
—
0
0
10
80
1.25
0.20
1.8
3.1
4.26
4.74
e9/l
—
10
80
6
48
1.25
0.20
1.0
1.1
—
—
—
0
0
7
61
1.15
0.17
1.0
1.0
—
—
—
0
0
8
68
1.18
0.16
1.4
1.6
—
—
—
0
0
56
526
1.07
0.16
2.4
2.5
4.70
9.54
umol/l
5.53
47
448
8
73
1.10
0.15
1.4
1.6
—
—
—
0
0
10
83
1.21
0.15
2.0
3.5
61.90
59.78
%
—
10
83
9
82
1.10
0.15
1.3
1.6
—
—
—
0
0
49
518
0.94
0.12
5.0
3.5
—
—
—
0
0
13
116
1.12
0.09
1.4
1.4
—
—
—
0
0
12
134
0.89
0.09
1.6
1.4
—
—
—
0
0
6
57
1.05
0.08
1.2
2.3
72.37
71.09
u/ml
—
6
57
6
58
1.03
0.08
2.2
4.3
—
—
—
0
0
7
67
1.05
0.08
1.0
1.1
—
—
—
0
0
10
112
0.89
0.07
1.6
1.9
—
—
—
0
0
9
86
1.05
0.07
1.7
1.5
307.98
306.71
mu/l
—
9
75
11
122
0.90
0.07
1.2
2.0
100.91
90.06
%
1.00
11
116
150
1476
1.02
0.06
3.7
3.3
79.12
109.29
e6/l
0.19
120
1142
55
568
0.97
0.06
4.1
6.3
1.62
1.32
mmol/l
0.24
36
453
22
233
0.94
0.06
1.8
3.4
25.95
24.22
mmol/l
1.59
22
225
123
1210
1.02
0.05
1.7
1.6
1.35
1.32
mmol/l
0.11
104
993
31
297
1.05
0.05
1.5
1.7
—
—
—
0
0
134
1358
0.98
0.04
3.5
3.2
0.43
0.47
e6/l
0.10
107
1030
34
346
0.98
0.00
1.9
2.0
—
—
—
0
0
117
1164
1.01
0.00
3.8
3.7
86.37
88.85
%
0.47
112
1136
31
314
0.99
0.00
1.9
1.9
—
—
—
0
0
80
803
1.00
0.00
3.6
3.1
0.96
0.76
ug/l
0.46
62
549
8
88
0.91
0.00
1.3
1.2
—
42.11
—
0
7
0
5
0.00
0.00
0.0
3.4
—
58.30
—
0
5
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
5
59
0.85
0.00
1.4
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
58
0.86
-0.00
1.2
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
7
75
0.93
-0.00
1.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
9.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
5
52
0.96
-0.00
1.2
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
50
1.00
-0.00
1.0
1.1
80.40
43.48
u/l
—
5
45
0
7
0.00
-0.00
0.0
11.4
—
6.81
—
0
7
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
24.38
—
0
9
Mortality – FinRegistry
↥Association
Association between endpoint H8_VERTIGOCENT and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H8_VERTIGOCENT | 1.227 [1.11, 1.36] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.01 |
During the follow-up period (1.1.1998 — 31.12.2019), 1126 out of 2537 females with H8_VERTIGOCENT died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H8_VERTIGOCENT | 1.266 [1.1, 1.45] | < 0.001 |
| Birth year | 0.989 [0.98, 1.0] | 0.021 |
During the follow-up period (1.1.1998 — 31.12.2019), 670 out of 1498 males with H8_VERTIGOCENT died.
Mortality risk
Mortality risk for people of age
years, who have H8_VERTIGOCENT.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.097% | 0.29% |
| 5 | 0.606% | 1.603% |
| 10 | 1.518% | 4.157% |
| 15 | 2.797% | 7.829% |
| 20 | 4.847% | 13.0% |
Relationships between endpoints
↥Index endpoint: H8_VERTIGOCENT – Vertigo of central origin
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data